<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352103</url>
  </required_header>
  <id_info>
    <org_study_id>9220</org_study_id>
    <nct_id>NCT02352103</nct_id>
  </id_info>
  <brief_title>Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery</brief_title>
  <official_title>The Impact of Retzius-sparing Approach for Robot-assisted Laparoscopic Radical Prostatectomy on Short-term Continence Recovery: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess and compare the short-term post-operative continence recovery rate in two cohorts
      of men undergoing Robot Assisted Radical Prostatectomy (RARP), each randomized to undergo
      RARP with Vattikuti Institute technique or Retzius sparing technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditionally, RARP is performed using a trans-peritoneal technique that pass anteriorly to
      the bladder. This technique necessitates the dissection and/or manipulation of many
      structures, which might compromise post-operative urinary continence recovery. These
      structures include the pubo-prostatic ligament, Santorini plexus, neurovascular bundle, and
      veil of Aphrodite. Recently, a &quot;Retzius-sparing&quot; technique to perform RARP has beed
      described. This approach passes posteriorly to the bladder, through the space of Douglas,
      which should minimize the damaged to the aforementioned structure. Theoretically, the latter
      technique should improve post-operative urinary continence recovery. However, a randomized
      comparison between the &quot;traditional&quot; RARP and &quot;Retzius-sparing&quot; RARP is still lacking.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">May 2032</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary continence recovery</measure>
    <time_frame>One week after the removal of the suprapubic urinary catheter</time_frame>
    <description>Number of pads and 24-hour pad weights</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary continence recovery</measure>
    <time_frame>within 3 months from the intervention</time_frame>
    <description>Two definitions shall be used: 0 pad/one security liner per day, and 0 pad per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri and postoperative morbidity and mortality</measure>
    <time_frame>1-year median follow up</time_frame>
    <description>Clavien-Dindo complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative sexual function, as measured by Sexual Health Inventory for Men (SHIM)</measure>
    <time_frame>1-year median follow up</time_frame>
    <description>Two definitions of potency shall be used: SHIM &gt;=17 and erections sufficient for penetrative intercourse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative oncological outcomes, as defined by post-operative Prostate-Specific antigen (PSA) value</measure>
    <time_frame>1-year median follow up</time_frame>
    <description>Patients who fail to reach a post-operative PSA vale &lt;0.01 ng/ml will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative urinary function and urinary function-related quality of life</measure>
    <time_frame>Within 3 months from the intervention</time_frame>
    <description>International Prostatic Symptom Score</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Urinary continence recovery</measure>
    <time_frame>1 year median follow up</time_frame>
    <description>Two definitions shall be used: 0 pad/one security liner per day, and 0 pad per day</description>
  </other_outcome>
  <other_outcome>
    <measure>Post-operative urinary function and urinary function-related quality of life</measure>
    <time_frame>1 year median follow up</time_frame>
    <description>International Prostatic Symptom Score</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vattikuti Urology Institute radical prostatectomy da Vinci Surgical System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retzius sparing radical prostatectomy da Vinci Surgical System</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Retzius sparing radical prostatectomy</intervention_name>
    <description>Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vattikuti Urology Institute radical prostatectomy</intervention_name>
    <description>Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>da Vinci Surgical System</intervention_name>
    <description>The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.</description>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with newly diagnosed prostate cancer undergoing robotic-assisted radical
             prostatectomy at the Vattikuti Urology Institute (performed by single surgeon, MM) as
             the primary treatment modality

          -  Be able to read and speak English and be able to provide written informed consent

        Exclusion Criteria:

          -  patients with high risk prostate cancer,defined as a biopsy Gleason score ≥8 and/or a
             pre-operative prostate specific antigen value ≥20 ng/ml.

          -  evidence of clinical nodal involvement (cN1) or metastatic disease (M1)

          -  patients participating in a competing study

          -  patients with pre-operative urinary incontinence.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mani Menon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford West Bloomfield Hospital</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Mani Menon</investigator_full_name>
    <investigator_title>Director, Vattikuti Urology Institute</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>Urinary continence</keyword>
  <keyword>robotic assisted radical prostatectomy</keyword>
  <keyword>Vattikuti Urology Institute (VIP) radical prostatectomy</keyword>
  <keyword>Retzius sparing radical prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

